FDA, Industry Should Prepare For Congressional Oversight Of REMS

FDA and industry need to prepare for congressional oversight of their compliance with the newly implemented Risk Evaluation & Mitigation Strategies, former Deputy Commissioner Scott Gottlieb said during FDC-Windhover's FDA/CMS Summit for Biopharma Executives Dec. 4